US IPO Pipeline SEC S-1 Filings — October 08, 2026

Pending merger with Seraphа Bio, Inc. (agreement June 22, 2026; subsequent event June 23, 2026) signals an active strategic combination with the S-4 filed October 8, 2026

S-4 for business combination with Elroy Air, Inc. filed October 8, 2026 (SEC File No. 333-299358) advances a SPAC-to-autonomous-aircraft transaction toward shareholder review

Open Market Sale Agreement referenced with a maximum offering size tagged April 1, 2025 indicates an at-the-market equity program is in place, a potential source of dilution alongside the merger

Name change from Columbus Circle Capital Corp II on September 26, 2025 signals sponsor-led repositioning ahead of the Elroy Air deal, consistent with a de-SPAC thesis

Lease activity recorded in April and May 2026 plus a new 2026 lease dated April 2026 suggests facility expansion or restructuring during the merger preparation period

Open Market Sale Agreement overhang combined with a pending merger raises potential share issuance; maximum offering size not legible in excerpt

Exchange ratio, consideration, and pro forma results are absent from the filing excerpt, so deal terms cannot be assessed

SPAC trust redemptions could leave the combined entity underfunded for an capital-intensive aircraft developer; trust balance not disclosed in excerpt

Autonomous aircraft development is pre-commercial hardware with regulatory certification hurdles; no revenue or cash metrics are legible to size the risk

Net loss, cash, and revenue figures for fiscal 2024, 2025, and first-half 2026 are referenced but not legible, preventing trend or runway analysis

Sponsor promote and dilution terms in the Inflection Point VII transaction are not visible, leaving sponsor-versus-public-holder alignment unverified

Pending merger with Seraphа Bio provides a defined catalyst; spread analysis requires exchange ratio and closing timeline from the full S-4

Public listing of an autonomous aircraft developer via SPAC offers exposure to an emerging-mobility theme; valuation can be benchmarked once pro forma figures are disclosed

SPAC trading near trust value offers downside protection through redemption rights until deal close, a common feature to verify in the proxy

Combination with Seraphа Bio may broaden the pipeline or cash base, a potential re-rating catalyst if synergy disclosures are strong

Elroy Air's entry via public markets offers a first-mover read on investor appetite for autonomous aviation hardware, relevant to peers in eVTOL and drone logistics

Both registrations are business-combination filings, with one SPAC-led transaction targeting capital-intensive autonomous aircraft; the theme is public-market access for pre-revenue hardware via S-4 structures, with redemption levels as the key variable

Boundless Bio's merger with Seraphа Bio reflects continued consolidation activity through stock-based combinations, with at-the-market financing overhangs as a common companion risk

Both October 8, 2026 S-4s provided header and XBRL data without legible deal economics, underscoring that investment decisions should await full prospectus disclosure and shareholder vote timing

Open Market Sale Agreements (Boundless Bio) and SPAC trust redemptions (Inflection Point VII) both introduce potential share supply that can pressure post-announcement pricing

Monitor SEC effectiveness and shareholder meeting date tied to the Seraphа Bio merger; S-4 filed October 8, 2026

Track full S-4 for exchange ratio, consideration mix, and pro forma financials to assess deal value

Watch for preliminary proxy statement details, trust balance, and redemption deadline following the October 8, 2026 S-4

Review revenue, cash burn, and capex plans in the proxy to gauge funding runway for autonomous aircraft development

Track Form 424B or 8-K disclosures for at-the-market sales that could signal dilution ahead of the merger close

Monitor for S-4/A amendments that would reveal updated financials and deal terms for the Elroy Air transaction